Navigation Links
Less Is More With Acute Myeloid Leukemia Drug
Date:3/16/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, March 16 (HealthDay News) -- A lower dose of the drug cytarabine work as well as the high doses that are typically used to treat acute myeloid leukemia, and with fewer side effects, a new Dutch study finds.

Cytarabine is used in the treatment of acute myeloid leukemia (AML), along with other chemotherapy drugs and stem cell transplantation. Cytarabine resembles a normal cell nutrient needed by cancer cells to grow. However, when these cells take up cytarabine, the drug actually interferes with their growth.

"The high-dose cytarabine schedules represent an unnecessary overdose causing excess toxicity with no apparent clinical benefit," said lead researcher Dr. Bob Lowenberg, a professor of hematology at Erasmus University Medical Center in Rotterdam. "The lower dose level is sufficient."

The report is published in the March 17 issue of the New England Journal of Medicine.

For the study, Lowenberg's team compared two different intravenous doses of cytarabine in patients with AML. One group of 431 patients was given a lower dose of the drug, while 429 were given a high dose, which is the current standard dose.

Patients who had a complete response to the drug after the first two cycles were taken off the drug, and treatment continued with another type of chemotherapy or a stem cell implant.

Over five years of follow-up, the researchers found no difference between the two groups in terms of remission. Eighty percent of those who received the lower dose had a complete remission, as did 82 percent of those who were given the higher dose.

There was also no significant difference in probability of relapse (34 percent of those given the lower dose and 35 percent of those who received the higher dose), or in overall survival (40 percent in the lower-dose group and 42 percent in the high-dose group).

Not only that, but patients receiving the high doses were more likely to suffer side effects than those given the lower doses, the researchers added. These included skin reactions and gastrointestinal and ocular toxic effects. Also, those given the high dose had longer hospital stays and delays in the recovery of white blood cells and platelets.

"The current standard of treatment with high-dose cytarabine, one of the major chemotherapeutic agents applied in the treatment of acute myeloid leukemia, represents an overdose," Lowenberg said.

One-tenth of the standard dose produces equally effective treatment, but with less toxicity, shorter hospital stays and fewer transfusions, he added.

"The lower-dose level also involves reduced costs," Lowenberg said. "These results set a new standard of care for the therapy of acute myeloid leukemia."

Dr. Mark H. Kirschbaum, an associate member for malignant hematology at the Nevada Cancer Institute in Las Vegas, said that "this is a very important study that will likely impact upon the treatment of patients with acute myeloid leukemia, particularly the older patient population, who clinically have always seemed to suffer from significant toxicity with higher-dose regimens."

"Hopefully progress in the molecular therapeutics of leukemia will allow us to more safely treat patients, particularly the older patients who make up the large majority of new AML patients, in a less toxic manner," he said.

More information

For more information on acute myeloid leukemia, visit the Leukemia & Lymphoma Society.

SOURCES: Bob Lowenberg, M.D., Ph.D., professor, hematology, Erasmus University Medical Center, Rotterdam, the Netherlands; Mark H. Kirschbaum, M.D., associate member, malignant hematology, Nevada Cancer Institute, Las Vegas; March 17, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Potential new treatment to reduce the burden of atherosclerosis in acute coronary syndrome patients
2. No Benefit to Lowering Blood Pressure in Acute Stroke: Study
3. Most X-Rays, Scans Unnecessary for Acute Low Back Pain
4. Researchers discover signaling pathway crucial to acute lung injury
5. Gene Activity May Affect Acute Myeloid Leukemia Outcome
6. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
7. Acute Cardiac Care 2010
8. Brain responds same to acute and chronic sleep loss
9. Diabetes patients admitted for acute exacerbations of COPD have longer hospital stay
10. Talyst Reaches Major Milestone: 500 Implementations in Long-Term Care, Acute Care and Corrections
11. Study finds rotavirus vaccine greatly reduces hospitalizations for acute gastroenteritis in children
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Less Is More With Acute Myeloid Leukemia Drug 
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... ... 2017 , ... Bill Howe started his sewer and drain company in 1980 ... joined the team, the Bill Howe brand was born and they began cultivating their ... back to the San Diego community in which they worked, lived and were raising ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA ... region. Côté has 20+ years of experience within the beauty industry, ranging from ... an array of high-end cosmetic brands, retail brands and outlets in Canada and ...
(Date:4/28/2017)... CA (PRWEB) , ... April 28, 2017 , ... NuevaCare, ... cities as diverse as Millbrae, Burlingame, and Palo Alto, is proud to announce information ... interested persons to bookmark and read organized content on topics such as home care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
Breaking Medicine Technology: